CD274 and non-small cell lung carcinoma: SA-49, a novel aloperine derivative, decreases the expression of PD-L1 on non-small cell lung cancer cells through promoting the translocation of PD-L1 for lysosomal degradation and subsequently enhancing the cytotoxicity of co-cultured T and NK cells.